ProCE Banner Series

Leveraging Real-world Insights to Inform Patient-Centered Care: Modern JAKi Strategies in Individualized Myelofibrosis Management

Join us to hear leading experts discuss the latest evidence and practical approaches to optimizing JAK inhibitor therapy for patients with myelofibrosis. Gain valuable insights to enhance patient outcomes and tailor treatments to meet individual needs in myelofibrosis care. Register now to be part of this dynamic local meeting series!

  AAPA
  | ACPE
  | AMA
  | ANCC
Who Should Attend

This activity has been designed to meet the educational needs of hematologists/oncologists, nurse practitioners, physician associates, oncology nurses, pharmacists, and other healthcare professionals involved in the management of myelofibrosis.

Faculty

ProCE Banner Faculty
John Mascarenhas, MD

Director
Center of Excellence in Blood Cancers and Myeloid Disorders
Director
Adult Leukemia Program
Leader
Myeloproliferative Disorders Clinical Research Program
Division of Hematology/Oncology
Tisch Cancer Institute
Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Topics

Optimizing JAK inhibitor therapy for patients with myelofibrosis

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
This program aims to improve learners' knowledge, competence, and performance in treating patients with myelofibrosis.

Target Audience
This activity has been designed to meet the educational needs of hematologists/oncologists, nurse practitioners, physician associates, oncology nurses, pharmacists, and other healthcare professionals involved in the management of myelofibrosis.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Accurately predict, based on evidence, patients with myelofibrosis who may be at risk for poor clinical outcomes

  • Implement patient-centered frontline therapy for patients with newly diagnosed myelofibrosis that addresses the individual needs and preferences of the patient, leveraging the expertise of the entire team

  • Sequence JAK inhibitor therapy for patients with myelofibrosis who experience intolerance to frontline therapy or disease progression after initial treatment, taking into consideration clinical and disease features and patient preferences

  • Coordinate care across specialties to recognize and effectively manage treatment-related toxicities in patients receiving JAK inhibitor therapies for myelofibrosis

Accreditation

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: Specific to each event

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.

CME Passport

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC

Supported by educational grants from CTI BioPharma Corp., a Sobi Company; and Incyte Corporation.